Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:AFFY OTCMKTS:AOLS OTCMKTS:CXRXF NASDAQ:ETNB OTCMKTS:MYRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAFFYAffymax$0.00+14.3%$0.00$0.00▼$0.00N/A7.3412,221 shs25,030 shsAOLSAeolus Pharmaceuticals$0.00$0.00▼$0.01N/A1.2835 shsN/ACXRXFADVANZ PHARMA$17.06$17.06$2.13▼$18.00$834.46MN/A11,851 shs39 shsETNB89BIO$10.73-0.4%$9.47$4.16▼$11.84$1.56B1.281.52 million shs238,333 shsMYRXMyrexis$0.00$0.00$0.00▼$0.01N/A0.6318 shsN/A(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAFFYAffymax-12.50%-12.50%-12.50%-12.50%0.00%AOLSAeolus Pharmaceuticals0.00%0.00%0.00%0.00%0.00%CXRXFADVANZ PHARMA0.00%0.00%0.00%0.00%0.00%ETNB89BIO+2.08%+6.31%+4.86%+94.94%+24.62%MYRXMyrexis0.00%0.00%+100.00%-97.14%-96.97%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAFFYAffymaxN/AN/AN/AN/AN/AN/AN/AN/AAOLSAeolus PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACXRXFADVANZ PHARMAN/AN/AN/AN/AN/AN/AN/AN/AETNB89BIO1.6226 of 5 stars3.51.00.00.01.10.80.6MYRXMyrexisN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAFFYAffymax 0.00N/AN/AN/AAOLSAeolus Pharmaceuticals 0.00N/AN/AN/ACXRXFADVANZ PHARMA 0.00N/AN/AN/AETNB89BIO 3.00Buy$26.43146.26% UpsideMYRXMyrexis 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest MYRX, ETNB, CXRXF, AOLS, and AFFY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/27/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)6/11/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)5/24/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)5/10/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)4/30/2025ETNB89BIOCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/24/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAFFYAffymaxN/AN/AN/AN/AN/AN/AAOLSAeolus PharmaceuticalsN/AN/AN/AN/AN/AN/ACXRXFADVANZ PHARMA$525.58M1.59N/AN/A$0.16 per share106.63ETNB89BION/AN/AN/AN/A$3.34 per shareN/AMYRXMyrexisN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAFFYAffymaxN/AN/A0.00∞N/AN/AN/AN/AN/AAOLSAeolus PharmaceuticalsN/AN/A0.00N/AN/AN/AN/AN/AN/ACXRXFADVANZ PHARMA-$74.86MN/AN/A∞N/A-15.31%N/A-4.38%N/AETNB89BIO-$367.08M-$3.38N/AN/AN/AN/A-81.44%-70.17%8/4/2025 (Estimated)MYRXMyrexisN/AN/A0.00∞N/AN/AN/AN/AN/ALatest MYRX, ETNB, CXRXF, AOLS, and AFFY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/4/2025Q2 2025ETNB89BIO-$0.49N/AN/AN/AN/AN/A5/1/2025Q1 2025ETNB89BIO-$0.50-$0.49+$0.01-$0.49N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAFFYAffymaxN/AN/AN/AN/AN/AAOLSAeolus PharmaceuticalsN/AN/AN/AN/AN/ACXRXFADVANZ PHARMAN/AN/AN/AN/AN/AETNB89BION/AN/AN/AN/AN/AMYRXMyrexisN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAFFYAffymaxN/AN/AN/AAOLSAeolus PharmaceuticalsN/AN/AN/ACXRXFADVANZ PHARMA257.042.391.61ETNB89BIO0.0618.0318.03MYRXMyrexisN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAFFYAffymaxN/AAOLSAeolus PharmaceuticalsN/ACXRXFADVANZ PHARMAN/AETNB89BION/AMYRXMyrexisN/AInsider OwnershipCompanyInsider OwnershipAFFYAffymax1.55%AOLSAeolus Pharmaceuticals66.60%CXRXFADVANZ PHARMAN/AETNB89BIO2.60%MYRXMyrexis0.01%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAFFYAffymax4N/AN/ANot OptionableAOLSAeolus Pharmaceuticals4N/AN/ANot OptionableCXRXFADVANZ PHARMA42948.91 millionN/ANot OptionableETNB89BIO40145.98 million142.19 millionOptionableMYRXMyrexis1N/AN/ANot OptionableMYRX, ETNB, CXRXF, AOLS, and AFFY HeadlinesRecent News About These CompaniesNo headlines for this company have been tracked by MarketBeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMYRX, ETNB, CXRXF, AOLS, and AFFY Company DescriptionsAffymax OTCMKTS:AFFY$0.0008 +0.00 (+14.29%) As of 11:28 AM EasternAffymax, Inc. does not have significant operations. Previously, it was developing drugs to enhance the treatment of serious and often life-threatening conditions in the United States. The company was founded in 2001 and is based in New York, New York.Aeolus Pharmaceuticals OTCMKTS:AOLSAeolus Pharmaceuticals, Inc., a biopharmaceutical company, develops a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious, and central nervous system diseases in the United States. The company develops a class of catalytic antioxidant compounds as medical countermeasures against nuclear, radiological, and chemical weapons, as well as for diseases and disorders of the respiratory system, central nervous system, and oncology. Its lead compound includes AEOL 10150 that has completed two Phase I clinical trials, which is developed against the pulmonary sub-syndrome of acute radiation syndrome; and for use as a medical countermeasure for exposure to chemical vesicants and nerve agents. The company is also developing AEOL 11114B, AEOL 11203, and AEOL 11207 for the treatment of Parkinson's disease, as well as AEOL 20415 for treating infectious diseases. Aeolus Pharmaceuticals, Inc. was founded in 1994 and is based in Mission Viejo, California.ADVANZ PHARMA OTCMKTS:CXRXF$17.06 0.00 (0.00%) As of 06/10/2021ADVANZ PHARMA Corp. Limited, a pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products worldwide. The company operates through two segments: ADVANZ PHARMA International and ADVANZ PHARMA North America. Its ADVANZ PHARMA International segment offers a portfolio of branded and generic prescription products to wholesalers, distributors, hospitals, and pharmacies. This segment's products include Brinavess for the conversion of onset atrial fibrillation to sinus rhythm in adults; Aggrastat, a reversible GP IIb/IIIa inhibitor indicated for use in patients with acute coronary syndrome; Xydalba, a semi-synthetic lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections in adults; and Zevtera/Mabelio, a cephalosporin antibiotic for the treatment of community-acquired and hospital-acquired pneumonia. The company's ADVANZ PHARMA North America segment provides Donnatal for the treatment of irritable bowel syndrome; Zonegran for the treatment of partial seizures in adults with epilepsy; Nilandron for the treatment of metastatic prostate cancer; Lanoxin for the treatment of mild to moderate heart failure and atrial fibrillation; Plaquenil for the treatment of lupus and rheumatoid arthritis; and Photofrin for the treatment of certain types of cancer. It also offers Prostaglandin E1 formulations for the treatment of erectile dysfunction and peripheral arterial occlusive disease under the Prostavasin, Viridal, Vasaprostan, and Edex brands, as well as holds licensed commercialization rights to a pre-registration drug/device combination product, Trevyent for the treatment of pulmonary arterial hypertension. It sells its products through direct sales and local distribution relationships. The company was formerly known as ADVANZ PHARMA Corp. and changed its name to ADVANZ PHARMA Corp. Limited in December 2019. ADVANZ PHARMA Corp. Limited is headquartered in London, the United Kingdom.89BIO NASDAQ:ETNB$10.73 -0.05 (-0.45%) As of 12:25 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.Myrexis OTCMKTS:MYRX$0.0002 0.00 (0.00%) As of 07/9/2025Myrexis, Inc. focuses on identifying, evaluating, and making financial investments in life sciences assets. The company was formerly known as Myriad Pharmaceuticals, Inc. and changed its name to Myrexis, Inc. in July 2010. Myrexis, Inc. is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Chipotle: Too Spicy for Smart Money to Resist After Stock Split Plug Power’s 20% Surge Signals New Commercial Growth Era Will Oracle's Cloud and AI Deals Propel It to New Highs? Enovix Shares Hit 6-Month High; Long-Term Highs to Follow Tesla Stock Could Accelerate on New EV Tax Legislation Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
